Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 5/20 | 0.41 |
| ▸ | ESR1 | P03372 | 6/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15969572 | 0.93 | CYP19A1 (0.49) | CYP19A1CYP26A1ESR1ESR2TSHR | |
| SCHEMBL15970366 | 0.86 | CYP19A1 (0.56) | CYP19A1CYP26A1ESR1ESR2CYP11B2 | |
| SCHEMBL15969586 | 0.80 | CYP19A1 (0.67) | CYP19A1CYP26A1TSHRCYP11B2MEN1 | |
| SCHEMBL15969815 | 0.76 | MTNR1A (0.39) | CYP19A1ESR1ESR2TSHRMEN1 | |
| SCHEMBL21478277 | 0.72 | CYP26A1 (0.39) | CYP19A1CYP26A1GAA | |
| SCHEMBL21474683 | 0.69 | MAOB (0.40) | TSHRMAOBMEN1KMT2A | |
| SCHEMBL8466193 | 0.66 | CYP19A1 (0.60) | CYP19A1CYP26A1MAOB | |
| SCHEMBL21478254 | 0.66 | MAOB (0.39) | TSHRMAOBMEN1KMT2A | |
| SCHEMBL21474591 | 0.64 | ACHE (0.38) | MAOBMEN1KMT2A | |
| SCHEMBL20809838 | 0.63 | CYP19A1 (0.68) | CYP19A1CYP26A1ESR2TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | CYP19A1 739/4885CYP26A1 1041/4885ESR1 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.